{"id":8581,"date":"2005-04-18T09:33:05","date_gmt":"2005-04-18T09:33:05","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=8581"},"modified":"2014-05-21T18:34:22","modified_gmt":"2014-05-21T18:34:22","slug":"omega-3-supplement-effective-to-reduce-triglycerides","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/8581","title":{"rendered":"Omega-3 supplement effective to reduce triglycerides"},"content":{"rendered":"

Simon Collins, HIV i-Base<\/strong><\/p>\n

In an oral presentation at the conference, a double blind, randomised trial carried out by French researchers with 122 subjects over 16 weeks showed the efficacy of using Omega-3 polyunsaturated fatty acids to treat hypertriglyceridaemia in patients receiving HAART.<\/strong><\/p>\n

Sixty HIV-positive patients received Maxepa capsules containing 1g fish oil (2 capsules, 3 times a day, 18% EPA, 12% DHA) and 62-patients received placebo (1g paraffin oil capsules), all of whom were receiving HAART and had high triglycerides greater than 2 g\/L after four weeks of appropriate dietary advice. Patients were given 8 weeks of treatment or placebo, followed by 8 weeks of open label treatment.<\/p>\n

The median change in triglycerides at week 8 was \u201325.5% in those receiving treatment compared to +1% in those on placebo. At the same point the mean triglycerides were 3.4 +\/-1.8 g\/L in those on treatment, and 4.8 +\/- 3.1 g\/L in the placebo group (whose only intervention had been dietary advice). Triglycerides were normalised in 22.4% of those receiving Maxepa, but in only 6.5% of those on placebo.<\/p>\n

During the open label period triglyceride reductions were maintained in those who had originally received Maxepa, and decreased by 21.2% in patients who had previously been given placebo.<\/p>\n

The researchers report that safety was good with no statistically significant differences being observed in the occurrence of adverse events between the two groups.<\/p>\n

Patients with baseline triglycerides >10g\/L were not randomised and received open label Maxepa. The mean decrease in triglycerides in this group was \u201335.6%.<\/p>\n

Hypertriglyceridaemia is a common blood lipid change seen in people on antiretroviral therapy and its increasing incidence is thought to be associated with high cardiovascular risk.<\/p>\n

The researchers concluded that the study demonstrated the efficacy of Omega-3 supplement to decrease triglycerides in ART-treated HIV-infected patients with baseline elevated triglycerides; and represented a potential option for first line therapy for ART-associated hypertriglyceridaemia because of its efficacy, good tolerance, and absence of drug interactions.<\/p>\n

Comment<\/h3>\n

This study looked at the use of 6 capsules of Maxepa per day (2 capsules 3 times a day), but some doctors recommend 5 capsules twice a day. However, many UK clinics prefer to use Omacor 1g capsules which contain 46% EPA and 38% DHA and require just 2 capsules twice a day. Both are available in the UK.<\/strong><\/p>\n

Reference:<\/p>\n

De Truchis P, Kirstetter M, Perier A et al. Treatment of hypertriglyceridemia in HIV-infected patients under HAART, by (n-3)polyunsaturated fatty acids: a double-blind randomised prospective trial in 122 patients. 12th CROI, 2005. Abstract 39<\/a>.<\/p>\n

OMACOR home page .
\n http:\/\/www.omacor.co.uk<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base In an oral presentation at the conference, a double blind, randomised trial carried out by French researchers with 122 subjects over 16 weeks showed the efficacy of using Omega-3 polyunsaturated fatty acids to treat hypertriglyceridaemia in …<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,8,27],"tags":[59],"class_list":["post-8581","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-side-effects","category-weight-diabetes-metabolic-complications","tag-croi-2005"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=8581"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8581\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=8581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=8581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=8581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}